Research to be presented highlighting potential of neuropsychological biomarkers to guide the clinical development of Cyclerion’s investigational therapeutics
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that it will present clinical trial design for a Phase 2a study of its lead development candidate, CY6463, in participants with Alzheimer’s disease with vascular pathology at the upcoming Alzheimer’s Association International Conference 2021 (AAIC). AAIC will be held July 26-30, 2021, virtually and in Denver, CO.
In addition, Anna Marin, a researcher in the laboratory of Dr. Andrew Budson and Dr. Katherine Turk in the Department of Neurology, Boston University School of Medicine and Center for Translational and Cognitive Neuroscience, VA Boston Healthcare System, will present results from the Cyclerion sponsored study on peak alpha frequency and N200 latency as predictors of neuropsychological performance in a memory disorders clinic. This pioneering work provides insights into the relationships between electrophysiological measures and cognitive performance in patients with Alzheimer’s disease and other dementias. Cyclerion identified changes in electrophysiological measures in the recent Phase 1 Translational Pharmacology study and will be evaluating electrophysiological and cognitive endpoints in the Phase 2a study in participants with Alzheimer’s disease with vascular pathology.
https://www.yahoo.com/entertainment/cyclerion-therapeutics-present-clinical-trial-203000086.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.